IPI-3063

Research use only, not for human use.

IPI-3063 is an effective and selective inhibitor of PI3K p110δ (IC50: 2.5 ± 1.2 nM).

IPI-3063 is an effective and selective inhibitor of PI3K p110δ (IC50: 2.5 ± 1.2 nM).

IPI-3063 inhibits p110α, p110β, and p110γ with IC50s of 1171±533 nM, 1508±624 nM, and 2187±1529 nM, respectively. IPI-3063 potently reduces mouse B cell proliferation, survival, and plasmablast differentiation while increasing antibody class switching to IgG1. IPI-3063 is a p110δ selective compound with an IC50=0.1?nM in p110δ-specific cell-based assays and cellular IC50 values for the other class I PI3K isoforms are at least 1,000-fold higher (IC50=1901±1318 nM for p110α, IC50=102.8±35.7 nM for p110β, IC50=418.8±117.2 nM for p110γ). IPI-3063 is very potent in reducing p-AKT (significant effect at 1?nM). IPI-3063 also reduces p-ERK1/2 with a significant effect at 10?nM. IPI-3063 is very potent, achieving a significant decrease in B cell survival when present at 10?nM.

——

——

PI3K/Akt/mTOR signaling

PI3K

p110α|p110β|p110γ|p110δ

——

——

1425043-73-7

455.51

C25H25N7O2

>98% (HPLC)

DMSO:83.33 mg/mL (182.94 mM)

C[C@@H](C1=CC2=C(C(=CC=C2)C3=CN(C(=O)C=C3)C)C(=O)N1C(C)C)NC4=NC=NC(=C4C#N)N

——

(-20℃)

With Ice Pack

≥ 2 years